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SHORT COMMUNICATION
Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics
of doxorubicin and doxorubicinol in mice
LK Webster', EJ Cosson', KH Stokes' and MJ Millward2
Divisions of 'Research and 2Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag No. 1, A'Beckett
Street, Melbourne, Victoria, Australia 3000.
Summary The effect of the paclitaxel vehicle Cremophor on the pharmacokinetics of doxorubicin and
doxorubicinol was studied in two groups of mice given intravenously either 2.5 ml kg- ' Cremophor or saline
followed 5 min later by 10 mg kg-' doxorubicin. In each group three mice were sacrificed at ten time points
and doxorubicin and doxorubicinol were measured in plasma by high-performance liquid chromatography
(HPLC). With Cremophor present, doxorubicin AUC increased from 1420+440 to 2770+660 ng h ml-'
(P<0.05) and doxorubicinol AUC increased from 130+ 76 to 320+ 88 ng h ml-' (P<0.05). Neither the
terminal elimination half-lives nor the doxorubicinol -doxorubicin AUC ratio changed in the presence of
Cremophor, suggesting lack of a direct effect on drug metabolism. The possibility exists that Cremophor may
change the pharmacokinetics of both paclitaxel and other drugs given concurrently.
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Multidrug resistance (MDR) is characterised by cellular
resistance to many natural products, including anthracy-
dlines and paclitaxel. Cremophor EL (Cremophor), a
polyethoxylated castor oil derivative used to solubilise
drugs, can reverse the MDR phenotype in vitro (Friche et
al., 1990; Woodcock et al., 1990; Chervinsky et al., 1993).
MDR modulators can change the pharmacokinetics of
cytotoxic drugs, including doxorubicin, often resulting in
increased toxicity and necessitating dose reductions (Lum et
al., 1992; Bartlett et al., 1994). Because Cremophor is a
potentially useful MDR modulator, it is important to
determine its effect on the pharmacokinetics of other drugs.
In addition, paclitaxel is formulated with Cremophor, and
plasma levels of Cremophor in patients following a 3 h
infusion of 135 or 175 mg m-2 paclitaxel are sufficient to
reverse MDR in vitro (Webster et al., 1993). Potential
pharmacokinetic interactions have been reported between
paclitaxel and doxorubicin (Holmes et al., 1994) and it is
possible that the Cremophor present in the paclitaxel vehicle
is contributing to the interaction. We therefore studied the
effect of Cremophor on the pharmacokinetics of doxorubicin
and its major metabolite, doxorubicinol, in mice.
Materials and methods
The study was approved by the institutional Animal
Experimentation Ethics Committee. Female Balb/c mice (9-
12 weeks, 18-24g) were housed in a constant temperature
facility with a 12 h light/dark cycle and had free access to food
and water. All drugs were injected intravenously in a tail vein
at 10 ml kg-'. Sterile Cremophor EL as 25% (v/v) in saline
(0.9% sodium chloride) and doxorubicin hydrochloride as
2 mg ml-' in saline were obtained from David Bull
Laboratories, Melbourne, Australia. Mice received either
Cremophor 2.5 ml kg-' or saline, followed 5 min later with
10 mg kg-' doxorubicin. In each group (Cremophor or saline
control), three mice were sacrificed at each of ten time points
following doxorubicin (5, 15, 30 min 1, 1.5, 2, 4, 8, 24, and
48 h) and bled into heparinised tubes to obtain plasma, which
was frozen until assay.
Doxorubicin and its major metabolite doxorubicinol were
measured by high-performance liquid chromotography
(HPLC) (Maessen et al., 1987) using 200 MI plasma. The
minimum quanitifiable concentration for both doxorubicin
and doxorubicinol (lowest concentration with a CV<20%)
was 0.5 ng ml-'. Standard non-compartmental pharmocoki-
netics was calculated (Gibaldi, 1991) and the results were
compared using the Student's t-test, accepting P < 0.05 as
statistically significant.
Results
The plasma concentrations for doxorubicin were higher at all
time points following Cremophor administration (Figure 1),
resulting in a 2-fold increase in the AUC (P<0.05, Table 1).
In addition, the peak concentration doubled, and doxor-
ubicin clearance decreased by 50%, but these differences did
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Figure 1 Semilogarithmic plasma concentration vs time curves
for doxorubicin and doxorubicinol in mice given intravenous
doxorubicin 10mgkg-1 Smin after either saline or Cremophor
2.5mlkg-'. Each point is the mean and standard error of the
mean for three individual mice. 0, Doxorubicin with saline; 0,
doxorubicin with Cremophor; M, doxorubicinol following
doxorubicin with saline; doxorubicinol following doxorubicin
with Cremophor. Concentrations of both doxorubicin and
doxorubicinol were higher at all timepoints when Cremophor
was present.
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Table I Doxorubicin and doxorubicinol pharmacokinetics in mice given 10 mg kg-' doxorubicin following either 10 ml kg' saline (control) oi
Cremophor (2.5 ml kg-')
Doxorubicin Doxorubicinol
Control With Cremophor Control With Cremophor
Cmax (ng ml') 750+ 120 1550 + 700 24+ 11 58+27
AUC (ng h ml-') 1420+440 2770+660* 130 +76 320+ 88*
Clearance (ml h-') 153 +57 75+ 21
ti (h) 16.3 + 3.0 14.0+0.6 27±6 23 +8
Vd (1) 2.7±0.5 1.0+0.3*
Mean ± s.d. (n =3). P<0.05, Student's t-test. AUC, area under the plasmaconcentration vstimecurve to infinity. t., terminalelimination half-life.
Vd, steady-state volume ofdistribution.
also decreased significantly. In contrast, the terminal
elimination half-life did not change.
When Cremophor was given before doxorubicin the peak
doxorubicinol plasma concentration was more than 2-fold
higher than with doxorubicin alone, and the levels remained
higher, resulting in a significant increase in the AUC (Figure
1, Table I). As with the parent drug, the terminal elimination
half-life was not altered. In addition, the ratio of the AUC of
doxorubicinol to doxorubicin did not decrease (0.093+0.042
in the control group and 0.155 +0.005 with Cremophor
pretreatment).
Discussion
The reversal of MDR by Cremophor in vitro is rapid and
reversible and may be either due to a direct interaction with
P-glycoprotein (P-gp) (Friche et al., 1990) or the result of a
general membrane,perturbation affecting its function (Sinic-
rope et al., 1992; Chervinsky et al., 1993). Administration of
Cremophor EL just before doxorubicin increased the
bioavailability of both doxorubicin and its major metabo-
lite, doxorubicinol, in mice. Cremophor has also been shown
to inhibit the elimination of etoposide in the isolated perfused
rat liver (Ellis et al., 1995). It is possible that Cremophor is
inhibiting P-gp-mediated biliary excretion of doxorubicin and
doxorubicinol. P-gp has been demonstrated in secretory
epithelial cells in the kidney, adrenal, liver and small
intestine (Borst et al., 1993), and there is evidence that P-gp
in the biliary canalicular membrane contributes to the biliary
excretion of many compounds, including doxorubicin (Speeg
and Maldonado, 1994).
It is unlikely that direct inhibition of cytochrome P450
metabolism by Cremophor contributed to the interaction,
since this would cause the doxorubicin elimination half-life to
increase and would possibly decrease the ratio of AUC of
metabolite to parent drug. However, Cremophor did decrease
the volume of distribution of doxorubicin and may therefore
have decreased or delayed liver uptake and consequently
inhibited clearance. Although only total doxorubicin was
measured, it is possible that Cremophor affected plasma
protein binding. Cremophor is known to associate in plasma
preferentially with low-density lipoproteins and at higher
concentrations it destroys high-density lipoproteins (Kong-
shaug et al., 1991). It has also been reported that Cremophor
apparently alters the biodistribution of paclitaxel by
decreasing its affinity to albumin and increasing its
association with low-density lipoproteins (Sykes et al., 1994).
Owing to the nature of the Cremophor bioassay (Webster
et al., 1993), it was not possible to measure Cremophor levels
in mice, but it is likely that they would approximate clinically
relevant concentrations. Because of its low water solubility,
paclitaxel for clinical use is formulated as 65 mg ml-' in 50%
Cremophor EL and 50% ethanol. A patient (1.8 m2) treated
with a standard dose of 175 mg m-2 paclitaxel (315 mg)
would also receive 26 ml of Cremophor, or 14.4 ml m-2. The
dose of Cremophor given to mice in the present study,
2.5 ml kg-', is equivalent to 7.5 ml m-2, which is approxi-
mately half the dose administered with paclitaxel.
Paclitaxel pharmacokinetics changes with dose and length
of infusion, such that decreasing the infusion time for the
same dose of paclitaxel, or increasing the dose for the same
infusion time, decreases the clearance, suggesting that
paclitaxel elimination is dose dependent (Sonnichsen and
Relling, 1994; Gianni et al., 1995). Alternatively, these non-
linear pharmacokinetics could be explained by a drug
interaction between Cremophor and paclitaxel similar to the
effect of Cremophor on doxorubicin in the present study.
Thus the varying plasma levels of Cremophor that would
occur with altered paclitaxel doses and infusion rates might
cause the pharmacokinetic changes.
In the present study Cremophor increased the bioavail-
ability of both doxorubicin and its major metabolite,
doxorubicinol, in mice. Although toxicity was not investi-
gated, the increased bioavailability might be expected to
increase the myelosuppression and cardiotoxicity associated
with doxorubicin. Owing to its administration in large
amounts during paclitaxel treatment, the possibility exists
that Cremophor may change the pharmacokinetics of both
paclitaxel and other drugs given concurrently, potentially
enhancing toxicity as well. In addition, patients receiving
Cremophor as an MDR modulator in combination with
cytotoxic drugs may also experience greater toxicity due to
altered pharmacokinetics of the cytotoxic agent.
References
BARTLETT NL, LUM BL, FISHER GA, BROPHY NA, EHSAN MN,
HALSEY J AND SIKIC BI. (1994). Phase I trial ofdoxorubicin with
cyclosporine as a modulator of multidrug resistance. J. Clin.
Oncol., 12, 835-842.
BORST P, SCHINKEL AH, SMIT JJM, WAGENAAR E, VAN DEEMTER
L, SMITH AJ, EIJDEMS EWHM, BAAS F AND ZAMAN GJR. (1993).
Classical and novel forms of multidrug resistance and the
physiological functions of P-glycoproteins in mammals. Pharma-
col. Ther., 60, 289-299.
CHERVINSKY DS, BRECHER ML, BAKER RM, HOELCLE MJ AND
TEBBI CK. (1993). Reversal of C1300 murine neuroblastoma
multidrug resistance by Cremophor EL, a solvent for Cyclosporin
A. Cancer Biother. , 8, 67-75.
ELLIS AG, CRINIS NA AND WEBSTER LK. (1995). Inhibition of
etoposide elimination in the isolated perfused rat liver by
Cremophor EL and Tween 80. Cancer Chemother. Pharmacol.,
(in press).
FRICHE E, JENSEN PB, SEHESTED M, DEMANT EJF AND NISSEN
NN. (1990). The solvents Cremophor EL and Tween 80 modulate
daunorubicin resistance in the multidrug-resistant Ehrlich ascites
tumor. Cancer Commun., 2, 297-303.
GIANNI L, KEARNS C, GIANI A, CAPRI G, VIGANO L, LOCATELLI
A, BONADONNA G AND EGORIN MJ. (1995). Nonlinear
pharmacokinetics and metabolism of paclitaxel and its pharma-
cokinetic/pharmacodynamic relationships in humans. J. Clin.
Oncol., 13, 180- 190..1 Doxorubicin pharmacokinetics with Cremophor
Xr.N. LK Webster et al
524
GIBALDI M. (1991). Compartmental and noncompartmental
pharmacokinetics. In Biopharmaceutics and Clinical Pharmacoki-
netics, 4th edn, pp. 14-23. Lea & Febiger: Philadelphia.
HOLMES FA, NEWMAN RA, MADDEN T, VALERO V, FRASCHINI G,
WALTERS RS, BOOSER DJ, BUZDAR AU, WILEY J AND
HORTOBAGYI UT. (1994). Schedule dependent pharmacoki-
netics in a phase I trial of Taxol and doxorubicin as initial
chemotherapy for metastatic breast cancer. Ann. Oncol., 5 (suppl
2), 197.
KONGSHAUG M, CHENG LS, MOAN J AND RIMINGTON C. (1991).
Interaction of Cremophor EL with human plasma. Int. J.
Biochem., 23, 473-478.
LUM BL, KAUBISCH S, YAHANDA AM, ADLER KM, JEW L, EHSAN
MN, BROPHY NA, HALSEY J, GOSLAND MP AND SIKIC BI.
(1992). Alteration ofetoposide pharmacokinetics and pharmaco-
dynamics by cyclosporine in a phase I trial to modulate multidrug
resistance. J. Clin. Oncol., 10, 1635- 1642.
MAESSEN PA, MROSS KB, PINEDO HM AND VAN DER VIJGH WJH.
(1987). Improved method for the determination of 4'-epidoxor-
ubicin and seven metabolites in plasma by high-pressure liquid
chromatography. J. Chrom., 417, 339-346.
SINICROPE FA, DUDEJA PK, BISSONNETTE BM, SAFA AR AND
BRASITUS TA. (1992). Modulation of P-glycoprotein-mediated
drug transport by alterations in lipid fluidity of rat liver
canalicular membrane vesicles. J. Biol. Chem., 267, 24995 -25002.
SONNICHSEN DS AND RELLING MV. (1994). Clinical pharmacoki-
netics of paclitaxel. Clin. Pharmacokinet., 27, 256- 269.
SPEEG VK AND MALDONADO AL. (1994). Effect of the non-
immunosuppressive cyclosporin analog SDZ PSC-833 on
colchicine and doxorubicin biliary secretion by the rat in vivo.
Cancer Chemother, Pharmacol., 34, 133 - 136.
SYKES E, WOODBURN K, DECKER D AND KESSEL D. (1994). Effects
of Cremophor EL on distribution ofTaxol to serum lipoproteins.
Br. J. Cancer, 70, 401 -404.
WEBSTER L, LINSENMEYER M, MILLWARD M, MORTON C,
BISHOP J AND WOODCOCK D. (1993). Measurement of
Cremophor EL following Taxol: Plasma levels sufficient to
reverse drug exclusion mediated by the multidrug-resistant
phenotype J. Nat! Cancer Inst., 85, 1685- 1690.
WOODCOCK DM, JEFFERSON S, LINSENMEYER ME, CROWTHER
PJ, CHOJNOWSKI GM, WILLIAMS B AND BERTONCELLO 1.
(1990). Reversal of the multidrug resistance phenotype with
Cremophor EL, a common vehicle for water-insoluble vitamins
and drugs. Cancer Res., 50, 4199-4203.